TY - JOUR
T1 - What you see is (not) what you get
T2 - tools for a non-radiologist to evaluate image quality in lung cancer
AU - de Jong, Evelyn E. C.
AU - Hendriks, Lizza E. L.
AU - van Elmpt, Wouter
AU - Gietema, Hester A.
AU - Hofman, Paul A. M.
AU - De Ruysscher, Dirk K. M.
AU - Dingemans, Anne-Marie C.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Medical images are an integral part of oncological patient records and they are reviewed by many different specialists. Therefore, it is important that besides imaging experts, other clinicians are also aware that the diagnostic value of a scan is influenced by the applied imaging protocol. Based on two clinical lung cancer trials, we experienced that, even within a study protocol, there is a large variability in imaging parameters, which has direct impact on the interpretation of the image. These two trials were: 1) the NTR3628 in which the added value of gadolinium magnetic resonance imaging (Gd-MRI) to dedicated contrast enhanced computed tomography (CE-CT) for detecting asymptomatic brain metastases in stage III non-small cell lung cancer (NSCLC) was investigated and 2) a sub-study of the NVALT 12 trial (NCT01171170) in which repeated F-18-fludeoxyglucose positron emission tomography (F-18-FDG-PET) imaging for early response assessment was investigated. Based on the problems encountered in the two trials, we provide recommendations for non-radiology clinicians, which can be used in daily interpretation of imaging. Variations in image parameters cannot only influence trial results, but sub-optimal imaging can also influence treatment decisions in daily lung cancer care, when a physician is not aware of the scanning details.
AB - Medical images are an integral part of oncological patient records and they are reviewed by many different specialists. Therefore, it is important that besides imaging experts, other clinicians are also aware that the diagnostic value of a scan is influenced by the applied imaging protocol. Based on two clinical lung cancer trials, we experienced that, even within a study protocol, there is a large variability in imaging parameters, which has direct impact on the interpretation of the image. These two trials were: 1) the NTR3628 in which the added value of gadolinium magnetic resonance imaging (Gd-MRI) to dedicated contrast enhanced computed tomography (CE-CT) for detecting asymptomatic brain metastases in stage III non-small cell lung cancer (NSCLC) was investigated and 2) a sub-study of the NVALT 12 trial (NCT01171170) in which repeated F-18-fludeoxyglucose positron emission tomography (F-18-FDG-PET) imaging for early response assessment was investigated. Based on the problems encountered in the two trials, we provide recommendations for non-radiology clinicians, which can be used in daily interpretation of imaging. Variations in image parameters cannot only influence trial results, but sub-optimal imaging can also influence treatment decisions in daily lung cancer care, when a physician is not aware of the scanning details.
KW - Non-small cell lung cancer
KW - Contrast-enhanced computed tomography
KW - Gadolinium-MRI
KW - F-18-FDG-PET
KW - Image guidelines
KW - BRAIN
KW - CELL
U2 - 10.1016/j.lungcan.2018.07.014
DO - 10.1016/j.lungcan.2018.07.014
M3 - Article
C2 - 30089580
SN - 0169-5002
VL - 123
SP - 112
EP - 115
JO - Lung Cancer
JF - Lung Cancer
ER -